GlobeNewswire 2011-12-12 Pharming granted U.S. patent on C1 inhibitor use in ischemia reperfusion injury indications
GlobeNewswire 2011-12-09 Pharming reports on negative equity position as a result of compliance with IFRS
GlobeNewswire 2011-12-07 Santarus and Pharming announce oral presentations of retrospective analyses of data from RHUCIN clin...
GlobeNewswire 2011-08-29 Pharming grants SOBI additional territories for the commercialisation of Ruconest®
GlobeNewswire 2011-08-15 Pharming announces extension of their license agreement for the commercialisation of Ruconest®
GlobeNewswire 2011-08-04 Pharming publishes financial report first half year 2011
GlobeNewswire 2011-07-21 Pharming completes a private placement raising €3.2 million
GlobeNewswire 2011-06-10 Granting of U.S. patent further extends protection of Pharming's core technology platform
GlobeNewswire 2011-06-07 Pharming signs commercialization agreement with MegaPharm for Ruconest® in Israel
GlobeNewswire 2011-06-01 Sapiens raises € 13m in a Series A financing to fund the development of a novel deep brain stimulati...
GlobeNewswire 2011-06-01 Sapiens raises € 13m in a Series A financing to fund the development of a novel deep brain stimulati...
GlobeNewswire 2011-05-23 New data support efficacy of Ruconest across all HAE attack locations
GlobeNewswire 2011-05-12 Pharming announces first quarter financial report 2011
GlobeNewswire 2011-03-21 Santarus and Pharming announce RHUCIN poster at American Academy of Allergy, Asthma & Immunology 201...
GlobeNewswire 2011-03-07 Socius exercises warrants
GlobeNewswire 2011-03-03 Pharming announces preliminary financial results 2010
GlobeNewswire 2011-02-28 Santarus and Pharming announce receipt of FDA refusal to file letter for RHUCIN Biologics License Ap...
GlobeNewswire 2011-02-22 Pharming and Santarus announce initiation of Phase IIIb clinical study with RHUCIN in Acute Heredita...
GlobeNewswire 2011-01-31 Pharming discontinues funding of DNage
GlobeNewswire 2010-12-28 Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
GlobeNewswire 2010-12-28 Pharming and Swedish Orphan Biovitrum announce first sales of Ruconest in Europe
GlobeNewswire 2010-12-06 Socius exercises investment rights
GlobeNewswire 2010-12-03 Pharming announces Euro 16.1 million investment from Socius Capital Group
GlobeNewswire 2010-12-02 Pharming awarded 'Best Biotechnology Company' by the World Technology Network
GlobeNewswire 2010-11-29 Pharming announces topline study results on prophylactic use of Ruconest in Hereditary Angioedema